Webinar - What are the strategies and key success factors for MedTech compani...Lea Bidiville
Join us on 15th September 2016, at 1.00pm BST to hear a panel of MedTech CEOs and investors discuss the challenges in securing investment in the sector and strategies for accessing capital
Benchmarking Professional Medical Education Excellence StructuresBest Practices
This document summarizes a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at large biopharmaceutical companies. Key findings include:
- Most companies take a centralized approach to medical education, located in their US market or headquarters country.
- Companies rely heavily on outsourcing, using vendors for 53% of program development and 58% of program delivery on average.
- Staffing is concentrated in North America, with an average of 5 FTEs and $3.23 million budget per FTE. Companies support an average of 170 CME and 98 non-CME programs annually.
Professional Medical Education Excellence PharmaBest Practices
Report Summary for "Professional Medical Education Excellence: Structures, Resources, Services & Performance Levels to Optimize Pharmaceutical Education Groups." Contact me to learn how to access the full report.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
This document summarizes a benchmarking study of new product planning structures and activities at 15 pharmaceutical and biotech companies. Key findings include:
- Global teams transition from planning to marketing earlier than regional teams.
- Global teams begin branding activities like naming in phase II, while regional teams start in phase III.
- Global teams value segmentation and positioning most, while regional teams value market research.
- Global new product planning is more centralized while regional structures are more hybrid.
Webinar - What are the strategies and key success factors for MedTech compani...Lea Bidiville
Join us on 15th September 2016, at 1.00pm BST to hear a panel of MedTech CEOs and investors discuss the challenges in securing investment in the sector and strategies for accessing capital
Benchmarking Professional Medical Education Excellence StructuresBest Practices
This document summarizes a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at large biopharmaceutical companies. Key findings include:
- Most companies take a centralized approach to medical education, located in their US market or headquarters country.
- Companies rely heavily on outsourcing, using vendors for 53% of program development and 58% of program delivery on average.
- Staffing is concentrated in North America, with an average of 5 FTEs and $3.23 million budget per FTE. Companies support an average of 170 CME and 98 non-CME programs annually.
Professional Medical Education Excellence PharmaBest Practices
Report Summary for "Professional Medical Education Excellence: Structures, Resources, Services & Performance Levels to Optimize Pharmaceutical Education Groups." Contact me to learn how to access the full report.
Medical Affairs Resources, Structures, and Trends (UPDATE) - Report SummaryBest Practices
The Update to the wildly popular Medical Affairs Resources, Structures, and Trends research from 2009 is ready! Contains linear data and new segmentation for emerging markets.
Charged with building and maintaining physician relationships, pharmaceutical Medical Affairs organizations typically oversee several important functions -- including publications, KOL programs, grants and medical education (CME) -- that have been impacted in recent years by a call for increased transparency. As such, forward-looking biopharmaceutical executives are beginning to evaluate Medical Affairs operations to ensure that the vital organization is appropriately structured and resourced to operate effectively in the current environment.
This Best Practices, LLC study explores how U.S. and global biopharmaceutical companies are structuring and managing their Medical Affairs organizations today. The study also examines recent trends in budget and staffing resources, key challenges and top success factors for the function.
The report is based on the insights of 68 Medical Affairs executives and managers at 50 leading global companies. The benchmark class in this study consists of a Mature Markets and Emerging Markets Segment. The Mature Market Segment includes 41 participants from pharma and 12 device respondents. The Emerging Markets Segment consists of 15 participants working in India, China, Brazil, and Turkey.
The document discusses the role and responsibilities of Medical Affairs departments within pharmaceutical companies. It describes how Medical Affairs operates medical information functions, provides insights from research to brand teams, cultivates relationships with key opinion leaders, and oversees publication planning and medical writing. Medical Affairs contributes to promotional review and provides market intelligence. The functions of Medical Affairs are organized globally and sometimes by business unit or therapeutic area at the local level. Key areas of specialization within Medical Affairs include medical services, medical research, and medical liaisons.
Growing Bio-pharma Digital Marketing Impact by Digitizing Launch, Developing ...Best Practices
It has become quite crucial to identify the drivers of digital marketing performance excellence in the health care industry which will enable companies to gain valuable customer insights, build effective relationships, leverage online media, and maximize revenue.
Best Practices, LLC undertook this benchmarking research to provide critical insights into how savvy bio-pharma digital marketers are enhancing the medical and commercial potential of new products, improving alignment with brand teams, acquiring and training new digital marketers, managing service delivery for key programs and optimizing insource vs. outsource mix.
Download Full Report: http://bit.ly/2gnXrIu
Drive Growth and Profitability Through Strategic Pharmaceutical New Product P...Best Practices
This document summarizes a benchmarking study of new product planning structures and activities at 15 pharmaceutical and biotech companies. Key findings include:
- Global teams transition from planning to marketing earlier than regional teams.
- Global teams begin branding activities like naming in phase II, while regional teams start in phase III.
- Global teams value segmentation and positioning most, while regional teams value market research.
- Global new product planning is more centralized while regional structures are more hybrid.
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
This document summarizes a study examining best practices for collaborating with patient advocacy groups. It provides an overview of the research methodology, participating companies, key findings and insights. Some of the main findings include: 1) there is no single best structure for patient advocacy groups, with companies taking decentralized, centralized and hybrid approaches; 2) social media and video platforms are increasingly important in patient education; and 3) transparency, aligning objectives, and trust are critical when working with advocacy groups on controversial therapies.
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
This document provides a summary of a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at major biopharmaceutical companies. Some key findings include:
- Most companies (over 75%) take a centralized approach to organizing their medical education functions. Nearly half centralize in the US.
- Companies heavily rely on outsourcing, delegating 86% of program development and all program deployment to vendors.
- Respondents were primarily directors or senior directors of medical education functions, with some managers. Insights were drawn from leaders across various roles and geographies.
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
This document summarizes research from a benchmarking study of regulatory affairs practices at 32 leading medical device companies. Key findings include:
- Regulatory affairs structures are most commonly centralized, though some utilize decentralized or hybrid models. Larger companies tend towards more decentralized structures.
- Portfolio complexity, defined as the ratio of class III products, influences but does not solely determine staffing needs.
- On average, companies file over a dozen submissions annually with European regulators and over 60 submissions with Japanese regulators.
- Regulatory staff spend significant time (over 20% for most companies) managing change notices and documentation.
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
The document provides a summary of research conducted on benchmarking advisory board management practices at mid-sized pharmaceutical and medical device organizations. Key findings from surveying 35 executives at 29 companies include that mid-sized companies have more advisory board participants on average compared to other companies, prefer national participants for clinical advisory boards, and face challenges in selecting appropriate advisory board members and managing advisory boards. The research was conducted to identify best practices for advisory board structure, selection of participants, operations, costs, and challenges.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
This document provides a summary of research on developing high-impact communication forms to brief senior leaders on competitive assessments and clinical development summaries. It describes the research methodology, which included surveys and interviews with leaders from 27 bio-pharma companies. Key findings include that executive briefs should be concise (5 pages or less), include general market insights as well as competitor insights, and be created for both new and existing products. Important elements to include are the condition treated, compound name, revenue projections, and probability of success. The document provides templates and recommendations for crafting impactful competitive landscape assessments and clinical development summaries.
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
This document summarizes the results of a benchmarking analysis that assessed the operational performance of managed markets functions at small and mid-sized pharmaceutical companies. The analysis found that on average these companies dedicate 55% of staff time to account management. It also found that companies feel they could operate with leaner structures, as the perceived ideal ratio of account managers to area directors is lower than current ratios. Additionally, the analysis showed that while account manager compensation is tied 50-50 to MBO and sales plan attainment, area directors compensation weighting shifts more to MBO at 60-40.
Infographic: Mastering Digital Marketing StructureBest Practices
The document discusses trends in digital marketing structure and budgets in the healthcare industry. It recommends reducing costs by outsourcing routine digital marketing functions like SEO. Most healthcare companies plan to increase their digital marketing budgets by over 10% in the next two years, though they currently lag in tracking digital marketing analytics compared to other industries. While 55% of US companies use a hybrid digital marketing structure, the overall trend is toward more centralized structures, as seen in 60% of all companies and 88% of innovative companies centralizing over the last two years.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Best-in-Class Strategies to Develop Effective Medical Information GroupsBest Practices
Medical information groups within bio-pharmaceutical companies play a vital role in the management of publications and product inquiries during the commercialization of drugs.
However, recent regulatory changes in the industry have made it imperative for the Medical Affairs function to align its medical information activities with compliance requirements.
This Best Practices, LLC report establishes benchmarks on the critical requirements to create strong medical information groups. In particular, this report identifies best practices in internal collaboration, alignment of information activities with compliance requirements and the structure, leadership and resource levels required to develop best-in-class medical information groups.
Download Full Report: http://bit.ly/2ewac07
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
This document summarizes a study examining best practices for collaborating with patient advocacy groups. It provides an overview of the research methodology, participating companies, key findings and insights. Some of the main findings include: 1) there is no single best structure for patient advocacy groups, with companies taking decentralized, centralized and hybrid approaches; 2) social media and video platforms are increasingly important in patient education; and 3) transparency, aligning objectives, and trust are critical when working with advocacy groups on controversial therapies.
Optimize the Role of Medical Affairs in Health Economics & Outcomes Research ...Best Practices
The Medical Affairs function plays an important role in health outcomes (HO) information exchange between bio-pharmaceutical organizations and key external stakeholders.
Development of robust health outcomes capabilities within Medical Affairs function requires an increase in the function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data as per stakeholders’ needs, and building real world data capabilities to generate and utilize health outcomes information.
This benchmarking research from Best Practices, LLC is designed to assist companies focused on oncology therapies find better ways to develop effective health outcomes groups. It provides current data and best practices from Medical Affairs leaders with an oncology focus at leading bio-pharmaceutical companies.
Download Full Report: http://bit.ly/2e3sl9Q
Strategies to Increase Medical Affairs' Role in Health Outcomes Data Generati...Best Practices
With the shift toward evidence-based medicine and value-based pricing, many bio-pharmaceutical companies are transitioning their Health Economics and Outcomes Research (HEOR) function away from the Commercial organization to Medical Affairs. This has some major implications towards the interactions with key stakeholders, the way interactions are documented and the skill sets & activities that may be required. Development of strong health outcomes capabilities within Medical Affairs organizations requires an increase in that function’s involvement with health outcomes groups, development of field-based health outcomes capabilities, customization of health outcomes data by stakeholders and building real world data capabilities to generate and utilize health outcomes information.
Best Practices, LLC undertook this study to identify strategies to increase MA’s role in Health Outcomes data generation and utilization. Specifically, the study highlights the role of Medical Affairs function in HO activities, industry drivers and resource levels for HO groups, challenges of MA’s involvement in HO activities and strategies for effective HO data communication and utilization.
Download Full Report: http://bit.ly/2dGFAbz
Benchmarking Bio-Pharmaceutical Medical Education Programs: Structures, Resou...Best Practices
This document provides a summary of a benchmarking study conducted by Best Practices, LLC on medical education structures, resources, and activities at major biopharmaceutical companies. Some key findings include:
- Most companies (over 75%) take a centralized approach to organizing their medical education functions. Nearly half centralize in the US.
- Companies heavily rely on outsourcing, delegating 86% of program development and all program deployment to vendors.
- Respondents were primarily directors or senior directors of medical education functions, with some managers. Insights were drawn from leaders across various roles and geographies.
Emerging Medical Education Trends in the Medical Device Industry: Benchmarks ...Best Practices
Medical education programs play an important role in informing health care professionals about the safe and effective use of medical devices.
To probe emerging medical education trends in the device sector, Best Practices, LLC undertook benchmarking research. In particular, this study provides benchmarks on the proper size, structure, funding channels, staffing and investment for medical education groups.
Download Full Report: http://bit.ly/2bY2NZ8
Delays in the launch and execution of critical market research projects can slow down the decision-making process, resulting in missed opportunities and increased costs. Therefore, it is absolutely critical for bio-pharmaceutical companies to develop a tactical approach to expedite the market research approval process for quicker and more meaningful insights.
According to recent research by Best Practices, LLC, nearly three-quarters of the benchmarked study participants use review cycle time as a metric for determining if the market research approval process is functioning at an acceptable level. One tip that participants gave on how to control processes and to ensure high performance is to create checklists. Begin with checklists in pinch points that are most problematic, and then extend to entire process and operations. This report will help leaders to gain critical insights they need to compete successfully in a fast-changing market.
Download Full Report: http://bit.ly/2bfAhOc
Given the stringent regulatory requirements in the health care industry, it is important for bio-pharmal companies to develop innovative Risk Evaluation and Mitigation Strategies (REMS) plans during the commercialization of certain products to ensure an acceptable risk-to-benefit ratio.
This benchmark study published by Best Practices, LLC examines how companies develop and execute successful Risk Evaluation and Mitigation Strategies (REMS) plans for newly-approved drugs in the U.S. market. This study can help bio-pharma companies in creating successful REMS programs.
Download Full Report: http://bit.ly/2aOt5Id
Budget Allocation for a Successful Bio-Pharma Product LaunchBest Practices
Bio-Pharma companies can no longer afford to rely solely on past experiences when budgeting for a new product launch in today's fast-changing, highly competitive market. This comprehensive benchmark study by Best Practices, LLC investigates current costs as well as budget and staffing allocations required for a successful drug launch.
This study can help bio-pharma leaders to develop competitive launch and pre-launch activity budgets to ensure successful U.S. market entry for new products.
Download Full Report: http://bit.ly/2aMYron
Driving Performance Excellence in the Regulatory Affairs Function at Medical ...Best Practices
This document summarizes research from a benchmarking study of regulatory affairs practices at 32 leading medical device companies. Key findings include:
- Regulatory affairs structures are most commonly centralized, though some utilize decentralized or hybrid models. Larger companies tend towards more decentralized structures.
- Portfolio complexity, defined as the ratio of class III products, influences but does not solely determine staffing needs.
- On average, companies file over a dozen submissions annually with European regulators and over 60 submissions with Japanese regulators.
- Regulatory staff spend significant time (over 20% for most companies) managing change notices and documentation.
Disease Awareness Program Excellence: Structure, Timing, Activities & Investm...Best Practices
Bio-pharmaceutical companies use disease state awareness campaigns to disseminate unbranded information to external stakeholders such as physicians, patients and payers.
Best Practices, LLC undertook research to deliver benchmarks around the structure, timing, investment and activities for disease awareness programs.
Download Full Report: http://bit.ly/2a7CnUS
Library Services Benchmarks - Using Corporate Library Services in PharmaBest Practices
Libraries are custodians of invaluable information. The study - Library Services Benchmarks 2016: Corporate Library Services in the Pharmaceutical Industry published by Best Practices, LLC examines the trends and staffing benchmarks such as library staff per potential and actual users across companies providing access to library services across the bio-pharmaceutical space.
This study looks into staff with formal education level and the number of staff inside and outside the library who provide library services. This study can be used by bio-pharmaceutical companies to improve upon existing library services and staffing.
Download Full Report: http://bit.ly/29QZcbM
Effective Launch Training Practices for District Sales Managers: Optimize Per...Best Practices
Rising competition and access restrictions in the bio-pharmaceutical industry have made it critical for companies to prepare and measure the performance of their District Sales Managers (DMs) who oversee launch-related activities in the field.
Best Practices, LLC engaged 20 sales leaders from bio-pharmaceutical companies to establish benchmarks around the training and accountability of District Sales Managers at launch. Insights from this study will serve as a reference point for companies to evaluate their launch training programs for the sales force against industry benchmarks.
Download Full Report: http://bit.ly/29Gq68L
Best Practices in Creating Global Brand for New Products and Ensuring Alignme...Best Practices
In order to develop an effective global branding program for new bio-pharmaceutical products, it is important to ensure brand consistency across all functions and geographies.
Best Practices, LLC undertook research to gather benchmarks on key aspects of the global branding process, including activities, timing, positioning, key message development, regional alignment, agency utilization & cost and the tradename process.
Download Full Report: http://bit.ly/2a1XqUV
Benchmarking Advisory Board Management at Mid-Sized Pharmaceutical & Medical ...Best Practices
The document provides a summary of research conducted on benchmarking advisory board management practices at mid-sized pharmaceutical and medical device organizations. Key findings from surveying 35 executives at 29 companies include that mid-sized companies have more advisory board participants on average compared to other companies, prefer national participants for clinical advisory boards, and face challenges in selecting appropriate advisory board members and managing advisory boards. The research was conducted to identify best practices for advisory board structure, selection of participants, operations, costs, and challenges.
This presentation gives an insight into the membership benefits of Best Practices, LLC’s Medical Affairs Consortium. It also highlights some of the key benchmarks and best practices that emerged from Medical Affairs Consortium.
The Medical Affairs Consortium at Best Practices, LLC provides a dedicated platform to Medical Affairs Leaders to discuss top challenges, develop action oriented solutions, share best practices & lessons learned and explore current and future trends with regards to the Medical Affairs function and its interactions with other critical functions.
Topics for the Medical Affairs Consortium are usually determined by member requests. The Medical Affairs Consortium addresses three key areas:
• Building Strong Medical Affairs Capabilities
• Medical Affairs Launch Support Excellence
• Medical Affairs’ Critical Role in Health Economics & Outcomes Research
Benchmarking Advisory Board Management At Large Pharmaceutical And Medical De...Best Practices
Pharmaceutical advisory boards provide strategic inputs and guidance to organizations on various business aspects. However, successful advisory board management requires optimum investment in resources and operations. To maximize the return on investment it is important for pharmaceutical and medical device professionals to ensure that the quality of meetings and dialogue with advisory boards is excellent.
This research from Best Practices, LLC is designed for pharmaceutical and biotech executives seeking ways to best utilize the knowledge of advisory boards. Research findings provide benchmarks on the appropriate structure for various types of advisory boards, selection of advisory board participants, advisory board operational and resource benchmarks.
Developing High-Impact Communication Forms to Brief Senior Leaders: Optimizin...Best Practices
This document provides a summary of research on developing high-impact communication forms to brief senior leaders on competitive assessments and clinical development summaries. It describes the research methodology, which included surveys and interviews with leaders from 27 bio-pharma companies. Key findings include that executive briefs should be concise (5 pages or less), include general market insights as well as competitor insights, and be created for both new and existing products. Important elements to include are the condition treated, compound name, revenue projections, and probability of success. The document provides templates and recommendations for crafting impactful competitive landscape assessments and clinical development summaries.
Optimizing the Managed Markets Function: Roles, Structures, Resources and Act...Best Practices
This document summarizes the results of a benchmarking analysis that assessed the operational performance of managed markets functions at small and mid-sized pharmaceutical companies. The analysis found that on average these companies dedicate 55% of staff time to account management. It also found that companies feel they could operate with leaner structures, as the perceived ideal ratio of account managers to area directors is lower than current ratios. Additionally, the analysis showed that while account manager compensation is tied 50-50 to MBO and sales plan attainment, area directors compensation weighting shifts more to MBO at 60-40.
Infographic: Mastering Digital Marketing StructureBest Practices
The document discusses trends in digital marketing structure and budgets in the healthcare industry. It recommends reducing costs by outsourcing routine digital marketing functions like SEO. Most healthcare companies plan to increase their digital marketing budgets by over 10% in the next two years, though they currently lag in tracking digital marketing analytics compared to other industries. While 55% of US companies use a hybrid digital marketing structure, the overall trend is toward more centralized structures, as seen in 60% of all companies and 88% of innovative companies centralizing over the last two years.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Giloy in Ayurveda - Classical Categorization and Synonyms
Medical Affairs Excellence Services Summary
1. Special Features
Annual Membership to the
Best Practice Database
provides unlimited access to
a $35-million growing
body of proprietary research
and forward-looking
analysis
Questions?
For more information, please contact
Best Practices LLC at (919) 403-0251 or
bestpractices@best-in-class.com
Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
Medical Affairs
Excellence
Services
PROJECT BACKGROUND
The dynamic bio-pharmaceutical and medical device
companies are accelerating their medical affairs function
scope beyond a traditional support function. The
function manages strategic responsibilities bridging
research as well as clinical
development, its scientific
publications strategy and
utilizes health outcomes,
biostatistics, necessary
medical education and
other medical services.
The medical affairs
function enhances a company’s scientific reputation and
complements the work of Research & Development. It
also provides physicians, key opinion leaders (KOLs),
legal-regulatory agencies, professional groups and
healthcare professionals with medical and scientific
information and education on the value and proper use
of a company’s products, therapies, devices, technology
and diagnostics.
During several years of benchmarking world-class
pharmaceutical and life science organizations, Best
Practices, LLC has provided valuable information to
pharmaceutical companies to improve their medical
affairs capabilities.
Copyright Best Practices, LLC (919) 403-0251 1
Overview
This Medical Affairs Excellence Services
provides executives with strategic insight
and successful approaches for competitive
performance in the medical affairs function. It
focuses on many areas including utilizing
health outcomes, scientific publications
strategy, educating physicians, key opinion
leaders, patient advocacy and clinical
developments.
Sample Featured Organizations
• Abbott Laboratories
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Cardiac Science Corp
• Eli Lilly
• GlaxoSmithKline
• Genentech
• Innovex
• Johnson & Johnson
• Novartis
• Pfizer Inc.
• Proctor & Gamble
• Sanofi-Aventis
• Schering Plough
• TEVA
Information Types
• 140+ Data Graphics
• 180+ Information Graphics
• 260+ Metrics
• 60+ Narratives
• 50+ Best Practices
2. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
Through the Medical Affairs Excellence Services, Best Practices provides our clients with the
insights, expertise and intelligence needed to increase the impact of Medical Affairs function
in the areas of:
• Medical Affairs structuring and funding
• Post-marketing surveillance for adverse events
• Thought leaders relationships
• Pharmaceutical speaker programs - training and development
• Scientific Publications strategy
• Medical Science Liaisons
• Key Opinion Leader Relationships
• Collaborating with patient advocacy groups
• New Product Planning
• Webinars for enhancing key opinion leader relationships
• Educating the marketplace for new Product launches – oncology
INCLUDED RESEARCH
Best Practices can tailor a service offering to meet your needs from our following products
and research. Contact us to discuss our services and pricing options for our research and
services which include:
1. Budget and Staffing Excellence: Benchmarking the Resources Required to Drive
Productivity and Growth (OP-97):
The study examines how the most successful pharmaceutical companies structure, align
staff and fund medical affairs capabilities.
Executives and managers can benchmark against these companies’ staffing and spend
levels; your company will gain the necessary information to conduct a performance gap
analysis using the following key metrics:
• FTEs by capability
• Imputed FTEs Per Dedicated MA Capability
• FTEs per compound
• FTEs per therapy area
• FTEs per $100 Million in US Sales
• Total Outsourcing by Company
• Outsourcing by Capability
• External Spend by Capability
Copyright Best Practices, LLC (919) 403-0251 2
3. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• External Spend per Compound
• Effectiveness by rating
2. Medical Affairs Resources, Structures & Trends (POP-228):
This benchmarking study explores how U.S. and global biopharmaceutical companies are
structuring and managing their Medical Affairs organizations today. The study also
examines recent trends in budget and staffing resources, key challenges and top success
factors for the function.
Specifically, the report highlights the following areas of medical affairs:
• Organizational Structure
• Reporting Relationship
• Job Level of Group Leader
• Geographic Span
• Budget Allocation by Medical Affairs Function
• Percent of Budget Allocated for Outsourcing
• Recent and Anticipated Changes in Resource Levels
• Impact of Medical Affairs Functions on Company Success
• Key Success Factors for Medical Affairs
• Key Challenges for Medical Affairs
3. Best Practices for Post-Marketing Surveillance of Adverse Events within the
U.S. (POP-230):
This benchmarking study examines the best practices for post-marketing surveillance
within the United States, as well as the processes for assessing reports of adverse
events, follow-up activities and compliance training.
Key elements of the report include:
• Staffing and Workflow
• Drug Safety Processes and Reporting Sources
• Approach to AE Reports from Non-Traditional Sources
• Approach to AE Reports on Another Manufacturer’s Product
• Drug Safety Compliance Training
• Marketing Program Involvement
Copyright Best Practices, LLC (919) 403-0251 3
4. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Drug Safety Challenges
4. Thought Leader Relationships: Building the Business (SM-129):
This study has captured the techniques that top pharmaceutical companies use to build
and manage thought leader relationships:
• Aligning Field-Based Medical with Overall Objective
• Managing Performance
• Providing Support and Communication
• Setting and Measuring Clear Goals
5. Pharmaceutical Speaker Programs: Building the Business (SM-130):
This Speaker Program Administration study identifies the top practices shared by
benchmark partners. Your company can use consolidated insights and best practices of
the benchmark class to guide thinking about your own physician relationship
management process.
The following include specific topics of concentration:
• Selecting System Logistics
• Using Vendors to Improve Performance
• The Internet
• Managing a World-Class System
• Implementation in the Field
• Budgeting
• Using Speaker Programs to Build Doctor Relationships
• Maximizing Influence in the Marketplace
• Creating Long-Term Benefits
• Ensuring Doctor Delight
• Training Reps, Speakers and Coordinators
• Setting Goals and Measuring Impact
• Doctor Response Matrix
• Reimbursement
• Communication
Copyright Best Practices, LLC (919) 403-0251 4
5. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Logistics
• Relationships
6. Best Practices in Speaker Training and Development: Driving Pharmaceutical
Brand Growth (SM-158):
This report focuses primarily on speaker training and development, a crucial link of the
entire speaker management process. Report owners will learn how top pharmaceutical
and biotech companies ensure the physicians that speak on their behalf are top-notch
communicators of product benefits. This study highlights speaker training program
logistics as well as the infrastructures companies have in place to develop physicians
into effective speakers.
• Training Program Design and Implementation
• Speaker Identification and Utilization
• Performance Measurement
• Governance Structure
• Resource Support
7. Educating the Market: Creating Value Through Support of Continuing Medical
Education (SM-180):
This study, based on benchmark survey data and executive interviews of participants
from several leading pharmaceutical, biotechnology and medical education companies,
was conducted to identify the salient trends and likely directions of Continuing Medical
Education's (CME) in the North American and European marketplaces. This report
provides benchmarks, insights and best practices in such key areas as:
• Geographic Delivery of CME
• Structural Management of CME
• CME Investment Budgets for North America & Europe
• Planned versus Spontaneous CME investment
• Functional Responsibility for CME
Copyright Best Practices, LLC (919) 403-0251 5
6. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• CME Delivery in North America (Company-directed versus 3rd party, etc.)
• CME Delivery in Europe
• Background & Experience of CME Employees
• Tenure of CME Employees
• Use of E-CME in North America & Europe
• Effectiveness Ratings for CME Delivery Activities in North America & Europe
The study also incorporates third-party input from seven CME vendors and eight medical
associations and teaching hospitals.
8. Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and
Commercial Relevance (PSM-220):
This research was launched to determine how leading pharmaceutical and biotechnology
companies are shaping their global publications strategies and plans in order to maintain
scientific credibility while also delivering commercially relevant publications that drive
brand success. Benchmark participants from 14 leading pharmaceutical companies
provided their insights and metrics to identify industry trends and performance
standards:
Key topics covered in the research:
• Global Publications Structure and Functional Home (Medical vs. Marketing)
• Key Contributors and Stakeholders in Strategy Development and Plan Delivery
• Effective Publications Vehicles, Content and Audiences
• Using Alternative Media
• Planning for Neutral/Negative Results
• Changes in Resources and Outsourcing
• Measuring Performance
• Strategic Next Steps
9. Medical Science Liaisons: Gaining Access and Forging Relationships with Key
Opinion Leaders (PSM-234):
Copyright Best Practices, LLC (919) 403-0251 6
7. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
As companies compete for the attention of physicians, key opinion leaders (KOLs) and
thought leaders, they increasingly use medical science liaisons (MSLs) to build and
strengthen KOL relationships. This research uncovers the optimal size, mix and service
frequencies of these elite medical specialist groups in an effort to build strong,
productive relationships.
Key topics covered in the research:
• Pre-Launch Service Activities
• Post-Launch Service Activities
• Drivers of Group Size & Focus
• Structuring & Aligning Field-Based Liaisons With Sales Organizations
• Optimal Call Frequencies and Service Levels with Thought Leaders
• Managing, Shifting & Forecasting Resources
10.Optimizing Key Opinion Leader Relationships: Best Practices in KOL
Management (PSM-235):
This report identifies the organizational structures, management strategies and tactics,
and critical success factors associated with KOL management excellence. Pharma
executives can use this benchmarking research to learn best practices in KOL
management and discover how they can maximize KOL relationships to benefit their own
products and therapies.
Included in the toolkit are the following research documents:
• KOL Segmentation and Behavior Drivers
• KOL Roles Over Product Lifecycle
• KOL Management Models
• Role of Medical Science Liaisons (MSLs) in Managing KOLs
• Emerging Trends in KOL Management
• Innovative Practices in KOL Management
• Critical Success Factors in KOL Management
• Most Difficult Challenges in KOL Management
11.Best Practices in Utilizing Health Outcomes Data for Promotional/ Commercial
Efforts (PSM-236):
Copyright Best Practices, LLC (919) 403-0251 7
8. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
This study aims to discover and collect best practices in how companies use and review
the use of Health Outcomes data in promotional/commercial settings. There is a focus
upon on-label, off-label and in-label promotions.
Included in the toolkit are the following research documents:
• Structure and Reporting Lines of Authority
• Health Outcomes Decisions
• Use of Health Outcomes Data Proactively and Retrospectively
• Who and How is Health Outcomes Data Utilized with Different Groups
• Health Outcomes Review Process and Structure
12.Collaborating with Patient Advocacy Groups to Educate the Marketplace (PSM-
242):
This comprehensive study analyzes the best practices from leading companies, narrates
their findings, details valuable statistics and, examines ideal structures and skill sets for
Pharma groups that deal with advocacy groups and emerging trends and challenges in
patient advocacy.
Included in the toolkit are the following research documents:
• Understanding the “advocacy” landscape
• Effective practices for working with potentially hostile patient advocacy groups
• Advocacy structures that work best
• Advocacy tools
• Critical competencies of Advocacy professionals
• Advocacy Lessons learned from socially sensitive or stigmatized disease areas
• Profiling Advocacy Group experience & expertise
13.New Product Planning for Medical Marketing Structure and Activities to Drive
Growth & Profitability (PSM-249):
This study examines the role and impact of New Product Planning (NPP) groups on
product commercialization efforts in pharmaceutical and biotech companies. It provides
reliable benchmarks, observations, and best practice insights to inform and shape
executive thinking around the challenges of new product development in medical
marketing.
Copyright Best Practices, LLC (919) 403-0251 8
9. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
Included in the toolkit are the following research documents:
• NPP group structures, roles and responsibilities
• Interactions and optimal working relationships between Regional and Global NPP
groups
• Examining the full set of activities NPP groups perform, their timing, intended
outcomes, and value for the organization
• The future of the NPP function
14.Webinar: Gaining Access & Forging Relationships with Key Opinion Leaders
(WEB-16):
Best Practices presented a webinar on "Gaining Access & Forging Relationships with Key
Opinion Leaders" – that showcased how top performing companies manage their Medical
Science Liaison function effectively and productively. Cameron Tew, an expert research
lead on this study, presented quantitative and qualitative data from our newly released
report.
15.Shaping the Marketplace to Support Successful Oncology Product Launches:
Tactics for Educating KOLs, Physicians, Patients and Payers (PSM-243):
This research informs launch leaders on the most effective physician, payer and patient
education practices conducted from clinical development through launch. Metrics address
KOL development tactics and timing, including MSL staff numbers and calls; Physician
education by publication type and timing and CME by type and timing; Patient and
Advocacy Group education by timing and type and Payer education by timing and type.
Included in the toolkit are the following research documents:
• Identification of Key Education Tactics for Thought Leaders, Physicians, Patients,
and Payers
• Identification of Key Timing for Educational Activities for KOLs, Physicians,
Patients and Payers
Copyright Best Practices, LLC (919) 403-0251 9
10. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Assessment of Key Market Education Practices, including Thought Leader
Activities, CME, Scientific Publication Strategy and Tactics, Patients and Patient
Advocacy Education, Clinical Trials & Payer Education
• Description of Critical Market Education Pitfalls and Future Trends
WHO CAN BENEFIT FROM THESE SERVICES?
These services provide valuable material for executives of the pharmaceutical organization
to ensure superior execution and implementation of medical affairs strategy and drive
operational efficiency. Executives will find numerous resource-related issues addressed,
while the execution level managers will be able to create roadmaps and plans for
accomplishing their objectives in key areas.
SAMPLE FINDINGS
• Medical Affairs Capabilities engagement
One medical affairs executive observed that companies do tend to “swing in a
pendulum” between positioning medical affairs under research and development and
under sales and marketing over time.
Pros and cons exist for these affiliations. When the medical affairs function is too closely
nested in research and development it tends to lose its focus on business goals and
objectives. On the other hand, if the medical affairs function is too closely aligned with
sales and marketing, scientific rigor is perceived as being lackluster - perhaps acting as
a disincentive for top medical talent.
• Spend allocation - Bulk of Medical Affairs Spending Goes to Clinical Functions
On average, more than a third of Medical Affairs spending goes to Medical/ Clinical
Research Operations. Benchmark participants spend as much as 98% of budgets on this
function.
Copyright Best Practices, LLC (919) 403-0251 10
11. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Reports of adverse events
Typically, reports of adverse events are driven by a company’s portfolio. Established
large companies with many products generated more than 1,000 reports a month while
smaller companies with fewer products reported less than 1,000 adverse events reports
a month.
• Field-Based Medical Management Process Map
Companies that have successfully implemented field-based medical management
describe a set of key benefits: faster sales uptake and better launch results, reduced
clinical trials costs and more useful results from trials, faster product development and
prolonged value from mature products through additional indications.
Copyright Best Practices, LLC (919) 403-0251 11
12. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Speaker Program Administration System Process Map
Companies that have successfully improved speaker program administration systems
describe a set of key benefits: higher speaker satisfaction, deeper relationships with key
Copyright Best Practices, LLC (919) 403-0251 12
13. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
speakers, reduced administrative costs, increased value for the larger sales and drug
development efforts and easier market education for new products.
• Maximizing the Use of Trained Speakers
Organizations that increase each trained speaker’s usage maximize investment, reduce
stale programs and avoid wasting resources training physicians that never deliver
presentations. Additionally, increased usage of all speakers raises the overall speaker
pool competency. The competency develops because each speaking engagement
advances a physician’s presentation capabilities. By requiring reps to schedule lesser-
used speakers for events, companies increase credibility, capitalize on training
investments and develop a deep pool of skilled speakers.
Copyright Best Practices, LLC (919) 403-0251 13
14. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Using Opportunities to Get the Funding for CME Programs
The amount of money required to fund CME programs can prove overwhelming for CME
organizations with small staffs. However, half of the surveyed participants from associations
and teaching hospitals reported that they received nearly all of the necessary money for
carrying out their programs.
• Key Contributors to Global Publications Strategy & Plan
Every company in the benchmark class turns to a medical director for strategy input. Most
companies also look to global brand directors and global publications directors. Overall,
responsibility for publications strategy is shifting from marketing brand leaders to global
publication, medical directors, or ‘neutral’-cross-functional teams.
Copyright Best Practices, LLC (919) 403-0251 14
15. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Pre-and Post-Launch Activities
While the majority of companies involve their MSLs in most pre-launch activities, some
choose to forego activities such as clinical protocol development, assisting with sales and
marketing plans and moderating advisory boards. Thought leaders are the compass to
competitor activities, market changes and early reactions to commercial products. Most
companies focus their medical specialists on developing KOLs to guide these post-launch
activities, as well as gathering competitive intelligence.
• Utilizing Health Outcomes Data for Promotional/ Commercial Efforts
Some Health Outcomes groups decide other points such as pricing and market access
strategies. However, these occur less frequently and seem to be activities that would be
undertaken by cross-functional groups or other areas within companies.
Copyright Best Practices, LLC (919) 403-0251 15
16. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Collaborating with Patient Advocacy Groups to Educate the Marketplace
Under-treated but recognized diseases may highlight public health issues. This can create
funding and collaboration opportunities for Pharma, Government and Patient Advocacy
Groups. In the case of PAD (Peripheral Arterial Disease), government funding underwrote
the creation of educational materials distributed by Pharma and advocacy groups.
Copyright Best Practices, LLC (919) 403-0251 16
17. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
• Shaping the Marketplace to Support Successful Oncology Product Launches:
Tactics for Educating Key Opinion Leaders (KOLs), Physicians, Patients and
Payers
This study explores best practices in educating, informing and preparing the marketplace for
new products –through Physician, Patient, and Payer education, publications, advocacy and
communication strategies.
Copyright Best Practices, LLC (919) 403-0251 17
18. Why Best Practices, LLC’s
Best Practice Database?
• The company we keep. With over
44,000 benchmark partners, we
work with a virtual Who’s Who list of
companies in dozens of industries.
This allows us to get the information
you need, when you need it
• We get our information from
the source; recognized industry
experts. It’s not just theory, the
best practices you will find are in
use today by leading companies
• Membership is constantly
increasing in value as more
research is added each month.
Why Best Practices, LLC’s
Best Practice Database?
• The company we keep. With more
than 44,000 benchmark partners,
we work with a virtual Who’s Who
list of companies in dozens of
industries. This allows us to get the
information you need, when you
need it
• We get our information from
the source; recognized industry
experts. It’s not just theory, the
best practices you will find are in
use today by leading companies
• Membership is constantly
increasing in value as more
research is added each month.
Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
BEST PRACTICE DATABASE
A research, analysis and decision-support service for
professionals working across functions such as
commercial operations, HR, R&D and customer service in
major industries including healthcare (Pharma, biotech,
med device, etc.), finance, manufacturing, technology
and communications. This insight-and-advisory service
delivers on-demand access to valuable performance
benchmarks and best practice research findings from
leading global companies. Membership in the Best
Practice Database provides unlimited access to a $40-
million growing body of proprietary research and forward-
looking analysis on topics such as:
• Sales force effectiveness
• Marketing performance
• New product launch
• Clinical operations
• Quality initiatives
• Leadership development
How can a membership benefit you?
Designed especially for business professionals like
yourself, Best Practice Database membership
allows you full access to $35 million in benchmarking
research.
Membership allows members to support daily,
process, productivity, and strategic decisions to
Copyright Best Practices, LLC (919) 403-0251 18
19. Medical Affairs Excellence Services: Research Excerpt (OPS-1A)
optimize their structure, build a business case for change, identify performance gaps,
and leverage executive insights to:
• Increase top-line revenue
• Enhance productivity and decrease costs
• Identify and retain key customers
Moreover, multi-seat “Star Access” (group membership) agreements (5, 10 or more seats)
can ensure that all your improvement staff can use a common platform for supporting large
initiatives and give you the flexibility of rotating users while offering attractive rates for
access to all our research.
For more details on the specific benefits of the Best Practice Database, go to
www.bestpracticedatabase.com/testimonials to learn how others use their Database access
to answer business questions, support a business case or serve internal clients.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a recognized leader in the field of best practice performance
improvement. Our suite of customized Research and Consulting services can assist in
improving your company's performance by analyzing the winning practices of leading
corporations and institutions.
Copyright Best Practices, LLC (919) 403-0251 19